·The phase III study in China has shown that Tenapanor significantly reduces elevated serum phosphorus (sP) levels in hemodialysis patients.
(12 July, 2023, Shanghai, China)Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that the New Drug Application (“NDA”) for Tenapanor Hydrochloride Tablets (the “New Drug”) for the control of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on hemodialysis, which was submitted by its holding subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharma Industrial") through license-in, was accepted for review by the National Medical Products Administration (“NMPA”).
Tenapanor is a First-in-class oral intestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor licensed by Fosun Pharma Industrial from Ardelyx, Inc.In December 2017, whereby Fosun Pharma Industrial was granted exclusive rights for the clinical development and commercialization of tenapanor in the regions including Mainland China, Hong Kong SAR and Macau SAR. Tenapanor, a chemical drug developed for the treatment of irritable bowel syndrome with constipation, was approved by the US Food and Drug Administration (“US FDA”) in September 2019, and the NDA for the New Drug as a medicine for the treatment of irritable bowel syndrome with constipation was also submitted in Hong Kong SAR in March 2023. As of the date, the phase I clinical trial of the New Drug for the indication of irritable bowel syndrome with constipation was completed in China (excluding Hong Kong, Macau and Taiwan regions), and the NDA for the New Drug used for the control of serum phosphorus in adult patients with CKD on dialysis is currently under US FDA regulatory review.
Tenapanor can reduce intestinal sodium ion absorption, increase the water in the intestinal lumen, promote intestinal peristalsis and the frequency of normal bowel movements.Several phase II and III studies in the United States and Japan have shown that tenapanor significantly reduces elevated serum phosphorus (sP) levels in hemodialysis patients, and also shown its therapeutic tolerability in the study of treatment duration up to 52 weeks. Without new safety signals identified1,2,3,the results of phase III study of tenapanor conducted in China are consistent with previously published research findings and support tenapanor as the medicine for the treatment of hyperphosphatemia in end-stage renal disease on hemodialysis (ESRD-HD) patients.On June 16, 2023, at the 68th Annual Meeting of the Japanese Society for Dialysis Therapy, Fosun Pharma orally presented the China Phase III results of tenapanor.
***
References:
1. Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30: 641–52.
2. Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep 2021; 7: 177–88.
3. Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2: 1600–10.
About Fosun Pharma
Founded in 1994,Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.
For more information, please visit our official website:www.fxcprm.com
Forward Looking Statement:
This press release contains a Forward Looking Statement. In addition to the historical factual statements contained in this press release, all the discussions, including but not limited to, discussions of our company's business strategy, discussions of future operations, profit margins, profitability, liquidity and capital resources, prospects for future development of our company's industry and future development of the economy in general in major markets, and any similar words or representations relating to our company or its management, whether before, after or including such words or representations as "expect", "seek", "believe", "plan", "intend", "estimate", "project", "expect", "may" and "will", are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions that may cause the actual results, performance or achievements of our company to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Therefore, you should not rely excessively on any forward-looking materials. Subject to the requirements of applicable laws, rules and regulations, our company has no obligation to update or otherwise modify the forward-looking statement in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, the statements or references to our company's intentions are effective as of the date of this press release. Any such intention may change with future developments. All the forward-looking statements contained in this press release are subject to the above cautionary statement.